2seventy bioNASDAQ: TSVT

The FDA's approval of 2seventy bio's Abecma for earlier treatment of relapsed/refractory multiple myeloma is a good development. Additionally, the decision to divest R&D assets to Regeneron is helping to reduce expenses.

2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.